Escalated hyperfractionated accelerated radiotherapy combined with chemotherapy for non-small cell lung cancer: a phase Ⅱ clinical trial

( views:, downloads: )
Chen Gui-yuan()
WANG Li-juan()
JIANG Guo-liang()
FU Xiao-long()
Qian Hao()
Zhao Sen()
Journal Title:
Volume 14, Issue 03, 2005
Key Word:


  • [1]Moore DF, Lee JS. Staging and prognostic factors: non-small cell lung cancer. In: Pass HI, Mitchell JB, Johnson DH, eds. Lung Cancer:principles and Practice. Philadelphia: Lippincott-Raven, 1996.481-494.
  • [2]Stewart LA, Pignon JP. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BM J, 1995,311: 899-909.
  • [3]Dillman RO, Herdon J, Seagren SL, et al. Improved survival in stage Ⅲ non-small cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst, 1996,88:1210-1215.
  • [4]le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonreseetable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst, 1991,83:417-423.
  • [5]Perez CA, Stanley K, Grundy G, et al. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Cancer, 1982,50: 1091-1099.
  • [6]Ang KK, Thames HD, Peters LJ. Altered fractionation schedules. In:Perez CA, Brady LW, eds. Principles and Practice of Radiation Oncology. 3rd ed. Philadelphia: Lippincott-Raven, 1998.119-142.
  • [7]Komaki R, Seiferheld W, Ettinger D, et al. Randomized chemoradiation for patients with locally advanced inoperable non-small coll lung cancer (NSCLC): long-term follow-up of RTOG 92-04. Ninth World Conference on Lung Cancer (IASLC), Tokyo, 2000.
  • [8]Saunders MI, Dische S, Barrett A, et al. Continuous hyperfractionted accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomized multicenter trial. Radiother Oncol,1999, 52:137-148.
  • [9]Dosoretz DE, Galmarini D, Rubenstein JH, et al. Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication. Int J Radiat Oncol Biol Phys, 1993,27:507-516.
  • [10]Perez CA, Bauer M, Edelstein S, et al. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys, 1986,12:539-547.
  • [11]Saunders MI, Barltrop MA, Rassa P, et al. The relationship between tumor response and survival following radiotherapy for carcinoma of the bronchus. Int J Radiat Oncol Biol Phys, 1984,10:503-508.
  • [12]Wilson GD, Mcnally NJ, Dische S, et al. Measurement of cell kinetics in human tumors in vivo using bromodeoxyuridine incorporation and flow cytometry. Br J Cancer, 1988,58: 423-431.
  • [13]Withers HR, Taylor JMG, Maciewjewski B, et al. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncologica, 1988,27:131 - 146.
  • [14]Fletcher GH. Clinical dose-response curves of human malignant epithelial tumors. Br J Radiol, 1973,46: 1-12.
  • [15]Chen M, Jiang GL, Fu XL, et al. The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer. Lung Cancer, 2000,28: 11-19.
  • [16]Harari PM.Adding dose escalation to accelerated hyperfractionation for head and neck cancer.Semin Radiat Oncol,1992.2:58-61.
  • [17]Schwade J,Markoe A,Abitbol A.Accelerating hyperfractionation for carcinoma of the head and reck.Semin Radiat Oncol,1992,2:51-53.
  • [18]Withers HR. Treatment induced accelerated human tumor growth. Semin Radiat Oncol, 1993,3:135-144.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615